In September 2019, Optinose announced a License Agreement with Currax Pharmaceuticals which grants Currax the exclusive rights to certain Optinose intellectual property for the purpose of marketing ONZETRA® XSAIL® (sumatriptan nasal powder) in the United States, Canada, and Mexico.
Other Partnerships and Technology Licenses
Although focused on development of its own proprietary new treatments, Optinose has allowed use of its technology by a small number of academic researchers and entered into technology licensing arrangements with carefully selected companies developing their own products that may benefit greatly from this unique type of drug delivery. If your research may benefit from the use of the unique Optinose delivery technology, please call or contact us using the link below.
Please contact us at firstname.lastname@example.org if your company is interested in exploring partnership opportunities for an innovative, non-oral or non-injected delivery platform for your proprietary CNS, systemic or topical nasal compounds.